AstraZeneca and BenevolentAI Completes Third Milestone in Their AI-Enabled Drug Discovery Cooperation
by AstraZeneca has identified an additional novel target for its drug development portfolio for idiopathic pulmonary fibrosis (IPF), allowing BenevolentAI, a leading clinical-stage AI-enabled drug discovery …